Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Stock Has Average Price Target of $43.90 According to Brokerages

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned a consensus rating of “Buy” from the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Twelve investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $43.90.

Several equities research analysts have recently commented on AAPG shares. Citizens Jmp began coverage on Ascentage Pharma Group International in a research note on Tuesday. They set a “market outperform” rating and a $35.00 price target on the stock. William Blair initiated coverage on Ascentage Pharma Group International in a report on Friday. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. dropped their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research note on Thursday, October 8th. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, Citigroup started coverage on Ascentage Pharma Group International in a report on Tuesday. They set a “buy” rating and a $46.00 price objective for the company.

Ascentage Pharma Group International Price Performance

Shares of AAPG opened at $14.69 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The firm’s 50-day moving average is $16.55 and its two-hundred day moving average is $19.11. Ascentage Pharma Group International has a twelve month low of $14.45 and a twelve month high of $37.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million for the quarter. As a group, sell-side analysts expect that Ascentage Pharma Group International will post -2.42 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.